Cargando…

Development of leading first-generation vaccines against SARS-CoV-2

SARS-CoV-2 has infected more than 167 million individuals globally. Highly effective and safe vaccines are required to accelerate the development of herd immunity to end the pandemic. This review focuses on vaccines that are being developed at unprecedented speed globally and are completing late pha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perera, Pin-Yu, Perera, Liyanage P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133830/ https://www.ncbi.nlm.nih.gov/pubmed/34022375 http://dx.doi.org/10.1016/j.micinf.2021.104841

Ejemplares similares

Willingness to get vaccinated with the first‐generation vaccines against SARS‐CoV‐2
por: Corbalán‐Fernández, Ana María, et al.
Publicado: (2022)

Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern
por: Al-Fattah Yahaya, Abdul Aziz, et al.
Publicado: (2023)

First-generation oral antivirals against SARS-CoV-2
por: Sendi, Parham, et al.
Publicado: (2022)

Next-Generation Vaccines: Nanovaccines in the Fight against SARS-CoV-2 Virus and beyond SARS-CoV-2
por: Mufamadi, Maluta Steven, et al.
Publicado: (2023)

T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV
por: Liu, William J., et al.
Publicado: (2017)

Timely development of vaccines against SARS-CoV-2
por: Lu, Shan
Publicado: (2020)

Development of an Inactivated Vaccine against SARS CoV-2
por: Pavel, Shaikh Terkis Islam, et al.
Publicado: (2021)

The development of DNA vaccines against SARS-CoV-2
por: Khalid, Kanwal, et al.
Publicado: (2023)

Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
por: Milne, Gregory, et al.
Publicado: (2021)

Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life
por: Zerbo, Ousseny, et al.
Publicado: (2023)

Phytochemicals against SARS-CoV as potential drug leads
por: Swain, Shasank Sekhar, et al.
Publicado: (2021)

Progress and Prospects on Vaccine Development against SARS-CoV-2
por: Zhang, Jinyong, et al.
Publicado: (2020)

Targets and strategies for vaccine development against SARS-CoV-2
por: Malik, Jonaid Ahmad, et al.
Publicado: (2021)

Development of DNA Vaccine Candidate against SARS-CoV-2
por: Wang, Xingyun, et al.
Publicado: (2022)

Potential SARS-CoV-2 main protease inhibitors
por: Banerjee, Riddhidev, et al.
Publicado: (2021)

Generation and Characterization of a Nanobody Against SARS-CoV
por: Li, Jiang-Fan, et al.
Publicado: (2021)

Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies
por: Terry, James S., et al.
Publicado: (2020)

Maternal SARS-CoV-2 Vaccination and Infant Protection Against SARS-CoV-2 During the First 6 Months of Life
por: Zerbo, Ousseny, et al.
Publicado: (2022)

SARS-CoV-2 infection triggers widespread host mRNA decay leading to an mRNA export block
por: Burke, James M., et al.
Publicado: (2021)

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma
por: Bird, Sarah, et al.
Publicado: (2021)

Timing vaccination against SARS-CoV-2
por: Barnoud, Coline, et al.
Publicado: (2021)

Vaccination of susceptible animals against SARS-CoV-2
por: Xiang, Bin, et al.
Publicado: (2022)

Nicotine has no significant cytoprotective activity against SARS-CoV-2 infection
por: Zheng, Fang, et al.
Publicado: (2022)

Development of vaccines for SARS-CoV-2
por: Ng, Wern Hann, et al.
Publicado: (2020)

SARS-CoV-2 vaccine development
por: Mtewa, Andrew G., et al.
Publicado: (2022)

New insights on possible vaccine development against SARS-CoV-2
por: Chaudhry, Sundas Nasir, et al.
Publicado: (2020)

Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2
por: Hudakova, Nikola, et al.
Publicado: (2021)

Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody
por: Terry, James S., et al.
Publicado: (2021)

Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys
por: Zielinski, Rafal J., et al.
Publicado: (2010)

First case of postmortem study in a patient vaccinated against SARS-CoV-2
por: Hansen, Torsten, et al.
Publicado: (2021)

The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2
por: Ho, Tzu-Chuan, et al.
Publicado: (2021)

Tropism of SARS-CoV-2, SARS-CoV, and Influenza Virus in Canine Tissue Explants
por: Bui, Christine H T, et al.
Publicado: (2021)

Molecular Characterization and Selection of Indigenous SARS-CoV-2 Delta Variant for the Development of the First Inactivated SARS-CoV-2 Vaccine of Pakistan
por: Aziz, Muhammad Waqar, et al.
Publicado: (2023)

Recombinant protein vaccines against SARS-CoV-2
por: Gilbert, Sarah C, et al.
Publicado: (2021)

Messenger RNA vaccines against SARS-CoV-2
por: Topol, Eric J.
Publicado: (2021)

Nucleic Acid Vaccines against SARS-CoV-2
por: Liu, Ying, et al.
Publicado: (2022)

Development of multi-epitope peptide-based vaccines against SARS-CoV-2
por: Lim, Hui Xuan, et al.
Publicado: (2021)

Development of an Oral Salmonella-Based Vaccine Platform against SARS-CoV-2
por: Yoon, Wonsuck, et al.
Publicado: (2022)

Vaccination strategies against SARS-CoV-2: General impact on the development of the pandemic
por: de Miguel, Ángel Gil, et al.
Publicado: (2021)

Development of a Multiepitope Vaccine Against SARS-CoV-2: Immunoinformatics Study
por: Ghafouri, Fatemeh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2013cippqlsrctlsgsp63cv3ob